COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
COMPASS Pathways plcNASDAQ: CMPS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $26.44M fell 14.4% year over year, behind the -12.0% change in trailing-twelve-month research & development. Sequentially, it fell 11.6% from the prior quarter. Over 3 fiscal years it compounded at +22.1% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -14.4% toward the trailing-twelve-month pace of -12.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 118.44M USD
- Year-over-year change
- -0.5%
- 4-year CAGR
- +28.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 118.44M | -0.5% |
| FY2024 | 2024-12-31 | 119.04M | +36.0% |
| FY2023 | 2023-12-31 | 87.52M | +34.5% |
| FY2022 | 2022-12-31 | 65.05M | +47.8% |
| FY2021 | 2021-12-31 | 44.03M | — |
Research & Development vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's LTM Mar 2026 research & development of $110.07M is the 8th highest of the 11 companies compared; the peer median is $196.42M.
- Its year-over-year change of -12.0% is the lowest of 10, against a peer median of +52.6%.
- Over three fiscal years its annual growth of +22.1% compares with a peer median of +31.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.27B | +80515.8% | -26.7% | — | |
| LTM Jun 2026 | $400.72M | -3.9% | +5.3% | 11118.8% | |
| LTM Sep 2026 | $319.46M | -7.3% | -3.1% | 26.6% | |
| LTM Sep 2026 | $289.11M | +17.6% | +19.9% | — | |
| LTM Jun 2026 | $220.87M | +52.6% | +38.8% | 23.0% | |
| LTM Mar 2026 | $171.97M | +136.8% | +73.1% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $169.81M | +60.3% | +48.2% | — |
| LTM Mar 2026 | $110.07M | -12.0% | +22.1% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M | +58.7% | +118.3% | 539.7% |
| LTM Mar 2026 | $43.27M | +26.5% | +23.7% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $28.47M | — | +131.7% | — |
| Peer median (excluding CMPS) | $196.42M | +52.6% | +31.2% | 283.1% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.03M | 65.05M | 87.52M | 119.04M | 118.44M |
| Selling, General & Admin | 39.19M | 45.35M | 49.4M | 59.17M | 60.6M |
| Operating Expenses | 83.22M | 110.4M | 136.92M | 178.21M | 179.04M |
| Depreciation & Amortization | 175K | 330K | 242K | 233K | 216K |
| EBITDA | (71.37M) | (90.77M) | (115.24M) | (148.82M) | (285.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (83.22M) | (110.4M) | (136.92M) | (178.21M) | (179.04M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 4.62M | 8.27M | 7.18M |
| Interest Expense | 0 | 0 | 2.2M | 4.48M | 4.52M |
| Other Income / Expenses | 11.68M | 19.31M | 19.24M | 24.68M | (111.3M) |
| Income Before Tax | (71.54M) | (91.1M) | (117.68M) | (153.53M) | (290.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 199K | 408K | 780K | 1.59M | (2.47M) |
| Net Income | (71.74M) | (91.51M) | (118.46M) | (155.12M) | (287.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| EPS (Diluted) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| Weighted Avg Shares | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
| Weighted Avg Shares (Diluted) | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.